Table 9.
The FDA-approved PARP inhibitors in cancer therapies
| Drug | Company | Indications | FDA approvals |
|---|---|---|---|
| Olaparib (Lynparza) | AstraZeneca | Ovarian (2014) | Olaparib capsules in patients with BRCA1/2 mutant advanced-stage ovarian cancers who have received ≥3 types of chemotherapies |
| Ovarian (2017) | Maintenance therapy for advanced -ovarian cancer patients with PR or CR to platinum-based chemotherapy | ||
| Ovarian (2018) | First-line maintenance therapy for patients with BRCA1/2 mutant advanced-stage ovarian cancers | ||
| Breast (2018) | Patients with BRCA1/2 mutant HER2-negative metastatic breast cancer who have been treated with chemotherapy | ||
| Breast (2022) | Patients with BRCA1/2 mutant HER2-negative high-risk early breast cancer who have been treated with adjuvant chemotherapy | ||
| Pancreatic (2019) | Adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma | ||
| Prostate (2020) | Adult patients with HRR gene mutated metastatic castration-resistant prostate cancer | ||
| Rucaparib (Rubraca) | Clovis Oncology | Ovarian (2016) | Patients with BRCA1/2-mutant ovarian cancer refractory to ≥ prior lines of treatment |
| Ovarian (2018) | Maintenance treatment of patients with recurrent ovarian cancer | ||
| Prostate (2020) | BRCA-mutated metastatic castration-resistant prostate cancer | ||
| Niraparib | Tesaro | Ovarian (2019) | Patients with HR deficiency -positive, advanced ovarian cancer |
| Ovarian (2020) | First-line maintenance treatment of patients with advanced ovarian cancer | ||
| Talazoparib | Pfizer | Breast (2018) | Patients with germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer |
Source: All the information is derived from the United States Food and Drug Administration.gov (https://www.fda.gov/)